Agenda
Agenda Topics
Over the course of two days Stanford Medicine will host the 9th Annual Sino-U.S. Symposium on Medicine in the 21st Century. The symposium will include a combination of panels, keynotes, and breakout sessions. The tentative agenda below shows the themes that will be addressed at this year's symposium. More information about speakers and moderators will be added in the near future.
Delegate registration will open on Wednesday, October 14.
Refreshments will be available in the lobby.
Opening remarks by members of the symposium committees.
Speakers
Roger and Joelle Burnell Professor of Genomics and Precision Health, Arthur L. Bloomfield Professor of Medicine and Professor of Genetics, of Biomedical Data Science and, by courtesy, of Pathology
Roger and Joelle Burnell Professor of Genomics and Precision Health, Arthur L. Bloomfield Professor of Medicine and Professor of Genetics, of Biomedical Data Science and, by courtesy, of Pathology
Roger and Joelle Burnell Professor of Genomics and Precision Health, Arthur L. Bloomfield Professor of Medicine and Professor of Genetics, of Biomedical Data Science and, by courtesy, of Pathology
Roger and Joelle Burnell Professor of Genomics and Precision Health, Arthur L. Bloomfield Professor of Medicine and Professor of Genetics, of Biomedical Data Science and, by courtesy, of Pathology
This profile is not available
Moderator
This profile is not available
This profile is not available
Speakers
This profile is not available
This profile is not available
Member, Board Of Trustees, Board of Trustees/University Governance
Li Ka Shing Professor in Cardiology
This profile is not available
Moderator
Director, Wu Tsai Human Performance Alliance at Stanford, James H. Clark Professor in the School of Engineering, Professor of Bioengineering and of Mechanical Engineering
Director, Wu Tsai Human Performance Alliance at Stanford, James H. Clark Professor in the School of Engineering, Professor of Bioengineering and of Mechanical Engineering
This profile is not available
Refreshments will be available in the lobby.
Speaker
This profile is not available
Moderator
This profile is not available
Speakers
Professor (Teaching) of Pediatrics (Neonatology) and, by courtesy, of Obstetrics and Gynecology
Professor (Teaching) of Pediatrics (Neonatology) and, by courtesy, of Obstetrics and Gynecology
Professor (Teaching) of Pediatrics (Neonatology) and, by courtesy, of Obstetrics and Gynecology
Professor (Teaching) of Pediatrics (Neonatology) and, by courtesy, of Obstetrics and Gynecology
This profile is not available
Moderator
This profile is not available
This profile is not available
Refreshments will be available in the lobby.
Speakers
This profile is not available
Thomas A. Raffin Professor of Medicine and Biomedical Ethics and Professor (Teaching) of Medicine (Primary Care and Population Health)
This profile is not available
Moderators
Professor (Research) of Pediatrics (Center for Biomedical Ethics) and of Medicine (Primary Care and Population Health)
Professor (Research) of Pediatrics (Center for Biomedical Ethics) and of Medicine (Primary Care and Population Health)
This profile is not available
Speakers
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Bio
Dr. Ford is a medical oncologist and geneticist at Stanford, devoted to studying the genetic basis of breast and GI cancer development, treatment and prevention. Dr. Ford graduated in 1984 Magna Cum Laude (Biology) from Yale University where he later received his M.D. degree from the School of Medicine in 1989. He was a internal medicine resident (1989-91), Clinical Fellow in Medical Oncology (1991-94), Research Fellow of Biological Sciences (1993-97) at Stanford, and joined the faculty in 1998. He is currently Professor of Medicine (Oncology) and Genetics, and Director of the Stanford Cancer Genetics Clinic and the Cancer Genomics Program at the Stanford University Medical Center.
Dr. Ford’s research goals are to understand the role of genetic changes in cancer genes in the risk and development of common cancers. He studies the role of the p53 and BRCA1 tumor suppressor genes in DNA repair, and uses techniques for high-throughput genomic analyses of cancer to identify molecular signatures for targeted therapies. Dr. Ford’s clinical interests include the diagnosis and treatment of patients with a hereditary pre-disposition to cancer. He runs the Stanford Cancer Genetics Clinic, that sees patients for genetic counseling and testing of hereditary cancer syndromes for prevention and early diagnosis of cancer in high-risk individuals and populations. He has recently been named the Director of Stanford’s new Cancer Genomics Program, performing next-generation tumor profiling to identify novel genetic targets for personalized targeted therapies, and directs the Molecular Tumor Board.
Dr. Ford is an editor of numerous scientific journals, including Cancer Research, DNA Repair, and PLoS Genetics. He has recently been named the founding Editor-in-Chief of JCO Precision Oncology.
.
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Bio
Dr. Ford is a medical oncologist and geneticist at Stanford, devoted to studying the genetic basis of breast and GI cancer development, treatment and prevention. Dr. Ford graduated in 1984 Magna Cum Laude (Biology) from Yale University where he later received his M.D. degree from the School of Medicine in 1989. He was a internal medicine resident (1989-91), Clinical Fellow in Medical Oncology (1991-94), Research Fellow of Biological Sciences (1993-97) at Stanford, and joined the faculty in 1998. He is currently Professor of Medicine (Oncology) and Genetics, and Director of the Stanford Cancer Genetics Clinic and the Cancer Genomics Program at the Stanford University Medical Center.
Dr. Ford’s research goals are to understand the role of genetic changes in cancer genes in the risk and development of common cancers. He studies the role of the p53 and BRCA1 tumor suppressor genes in DNA repair, and uses techniques for high-throughput genomic analyses of cancer to identify molecular signatures for targeted therapies. Dr. Ford’s clinical interests include the diagnosis and treatment of patients with a hereditary pre-disposition to cancer. He runs the Stanford Cancer Genetics Clinic, that sees patients for genetic counseling and testing of hereditary cancer syndromes for prevention and early diagnosis of cancer in high-risk individuals and populations. He has recently been named the Director of Stanford’s new Cancer Genomics Program, performing next-generation tumor profiling to identify novel genetic targets for personalized targeted therapies, and directs the Molecular Tumor Board.
Dr. Ford is an editor of numerous scientific journals, including Cancer Research, DNA Repair, and PLoS Genetics. He has recently been named the founding Editor-in-Chief of JCO Precision Oncology.
.
This profile is not available
Moderators
Karel H. and Avice N. Beekhuis Professor of Cancer Biology
Karel H. and Avice N. Beekhuis Professor of Cancer Biology
This profile is not available
The reception and dinner will be held in Berg Hall from 5-8 p.m.
Refreshments will be available in the lobby.
Speaker
This profile is not available
Moderator
Dr. Morris Herzstein Professor in Biology, Emeritus
Speakers
Dr. Morris Herzstein Professor in Biology, Emeritus
William M. Hume Professor in the School of Medicine, Professor of Biomedical Data Science and of Radiology
Stanford W. Ascherman Professor of Genetics
Stanford W. Ascherman Professor of Genetics
This profile is not available
Moderator
Professor of Medicine (Hematology) and of Genetics
Bio
In perpetual awe of how 'simple' microbial organisms can perturb complex, multicellular eukaryotic organisms, Ami Bhatt has chosen to dedicate her research program to inspecting, characterizing and dissecting the microbe-human interface. Nowhere is the interaction between hosts and microbes more potentially impactful than in immunocompromised hosts and global settings where infectious and environmental exposures result in drastic and sometimes fatal health consequences.
Ami's group identifies problems and questions that arise in the course of routine clinical care. Often in collaboration with investigators at Stanford and beyond, the group applies modern genetic, molecular and computational techniques to seek answers to these questions, better understand host-microbe interactions and decipher how perturbation of these interactions may result in human disease phenotypes.
Professor of Medicine (Hematology) and of Genetics
Bio
In perpetual awe of how 'simple' microbial organisms can perturb complex, multicellular eukaryotic organisms, Ami Bhatt has chosen to dedicate her research program to inspecting, characterizing and dissecting the microbe-human interface. Nowhere is the interaction between hosts and microbes more potentially impactful than in immunocompromised hosts and global settings where infectious and environmental exposures result in drastic and sometimes fatal health consequences.
Ami's group identifies problems and questions that arise in the course of routine clinical care. Often in collaboration with investigators at Stanford and beyond, the group applies modern genetic, molecular and computational techniques to seek answers to these questions, better understand host-microbe interactions and decipher how perturbation of these interactions may result in human disease phenotypes.
This profile is not available
Refreshments will be available in the lobby.
Speaker
Member, Board Of Trustees, Board of Trustees/University Governance
Moderator
This profile is not available
Speakers
George E. and Lucy Becker Professor in Medicine
George E. and Lucy Becker Professor in Medicine
This profile is not available
Moderators
Rachford and Carlota Harris Professor
Bio
Dr. Nolan is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore (for postdoctoral work for the first cloning/characterization of NF-κB p65/ RelA and the development of rapid retroviral production systems). He has published over 350 research articles and is the holder of 50 US patents, and has been honored as one of the top 25 inventors at Stanford University.
Dr. Nolan is the first recipient of the Teal Innovator Award (2012) from the Department of Defense (a $3.3 million grant for advanced studies in ovarian cancer), the first recipient of an FDA BAAA, for “Bio-agent protection” grant, $3million, from the FDA for a “Cross-Species Immune System Reference”, and received the award for “Outstanding Research Achievement in 2011” from the Nature Publishing Group for his development of CyTOF applications in the immune system. Dr. Nolan has new efforts in the study of Ebola, having developed instrument platforms to deploy in the field in Africa to study Ebola samples safely with the need to transport them to overseas labs (funded by a new $3.5 million grant from the FDA) and another grant to study the effects of Zika and Ebola viruses on humans (also from the FDA).
Dr. Nolan is an outspoken proponent of translating public investment in basic research to serve the public welfare. Dr. Nolan was the founder of Rigel Inc. (NASDAQ: RIGL), and Nodality, Inc. (a diagnostics development company), BINA (a genomics computational infrastructure company sold to Roche Diagnostics), Founder of Apprise (sold to Roche Sequencing Solutions), co-Founder of Ionpath, co-Founder of Akoya, and serves on the Boards of Directors of several companies as well as consults for other biotechnology companies. DVS Sciences, on which he was Chair of the Scientific Advisory Board, recently sold to Fluidigm for $207 million dollars (2014) on an investment of $14 million. Dr. Nolan is a member of the Parker Institute for Cancer Immunotherapy at Stanford.
His areas of research include hematopoiesis, cancer and leukemia, autoimmunity and inflammation, and computational approaches for network and systems immunology. Dr. Nolan’s recent efforts are focused on a single cell analysis advance using a mass spectrometry-flow cytometry hybrid device, the so- call “CyTOF” and the “Multiparameter Ion Beam Imager” (MIBI) developed by Dr. Mike Angelo in his lab (Dr. Angelo is now an Assistant Professor in the Dept of Pathology at Stanford). The approaches use an advanced ion plasma source to determine the levels of tagged reagents bound to cells—enabling a vast increase in the number of parameters that can be measured per cell—either as flow cytometry devices (CyTOF) or imaging platforms for cancer (MIBI). Further efforts with another imaging platform termed CODEX (Akoya, Inc.) that inexpensively converts fluorescence scopes to high dimensional imaging platforms.
Dr. Nolan’s efforts are to enable a deeper understanding not only of normal immune function, trauma, pathogen infection, and other inflammatory events but also detailed substructures of leukemias and solid cancers and their interactions with the immune system—which will enable wholly new understandings that will enable better management of disease and clinical outcomes.
Rachford and Carlota Harris Professor
Bio
Dr. Nolan is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. He trained with Leonard Herzenberg (for his Ph.D.) and Nobelist Dr. David Baltimore (for postdoctoral work for the first cloning/characterization of NF-κB p65/ RelA and the development of rapid retroviral production systems). He has published over 350 research articles and is the holder of 50 US patents, and has been honored as one of the top 25 inventors at Stanford University.
Dr. Nolan is the first recipient of the Teal Innovator Award (2012) from the Department of Defense (a $3.3 million grant for advanced studies in ovarian cancer), the first recipient of an FDA BAAA, for “Bio-agent protection” grant, $3million, from the FDA for a “Cross-Species Immune System Reference”, and received the award for “Outstanding Research Achievement in 2011” from the Nature Publishing Group for his development of CyTOF applications in the immune system. Dr. Nolan has new efforts in the study of Ebola, having developed instrument platforms to deploy in the field in Africa to study Ebola samples safely with the need to transport them to overseas labs (funded by a new $3.5 million grant from the FDA) and another grant to study the effects of Zika and Ebola viruses on humans (also from the FDA).
Dr. Nolan is an outspoken proponent of translating public investment in basic research to serve the public welfare. Dr. Nolan was the founder of Rigel Inc. (NASDAQ: RIGL), and Nodality, Inc. (a diagnostics development company), BINA (a genomics computational infrastructure company sold to Roche Diagnostics), Founder of Apprise (sold to Roche Sequencing Solutions), co-Founder of Ionpath, co-Founder of Akoya, and serves on the Boards of Directors of several companies as well as consults for other biotechnology companies. DVS Sciences, on which he was Chair of the Scientific Advisory Board, recently sold to Fluidigm for $207 million dollars (2014) on an investment of $14 million. Dr. Nolan is a member of the Parker Institute for Cancer Immunotherapy at Stanford.
His areas of research include hematopoiesis, cancer and leukemia, autoimmunity and inflammation, and computational approaches for network and systems immunology. Dr. Nolan’s recent efforts are focused on a single cell analysis advance using a mass spectrometry-flow cytometry hybrid device, the so- call “CyTOF” and the “Multiparameter Ion Beam Imager” (MIBI) developed by Dr. Mike Angelo in his lab (Dr. Angelo is now an Assistant Professor in the Dept of Pathology at Stanford). The approaches use an advanced ion plasma source to determine the levels of tagged reagents bound to cells—enabling a vast increase in the number of parameters that can be measured per cell—either as flow cytometry devices (CyTOF) or imaging platforms for cancer (MIBI). Further efforts with another imaging platform termed CODEX (Akoya, Inc.) that inexpensively converts fluorescence scopes to high dimensional imaging platforms.
Dr. Nolan’s efforts are to enable a deeper understanding not only of normal immune function, trauma, pathogen infection, and other inflammatory events but also detailed substructures of leukemias and solid cancers and their interactions with the immune system—which will enable wholly new understandings that will enable better management of disease and clinical outcomes.
This profile is not available
Speakers
Rachael L. and Walter F. Nichols, MD, Professor and Professor, by courtesy, of Education and of Neurology and Neurological Sciences
Bio
Dr. Menon is the Rachel L. and Walter F. Nichols, MD, Professor of Psychiatry & Behavioral Sciences and, Professor, by courtesy, of Neurology & Neurological Sciences and Education at Stanford University. Dr. Menon is director of the Stanford Cognitive and Systems Neuroscience Laboratory, which seeks to advance fundamental knowledge of human brain function and dysfunction, and to use this knowledge to help children and adults with psychiatric and neurological disorders. Research in Dr. Menon's lab emphasizes a tight integration of cognitive, behavioral, neuroscience and computational methodologies. Students and researchers in his lab come from a wide range of disciplines, including psychiatry, neurology, psychology, neuroscience, electrical and biomedical engineering, and computer science, to conduct research in a highly interdisciplinary setting.
Dr. Menon received his BSc (Honors) in physics from the Indian Institute of Technology and his PhD in computer science from the University of Texas at Austin. He did a postdoctoral fellowship in neurophysiology at the University of California, Berkeley under the direction of Prof. Walter J. Freeman, III. He came to Stanford University as a Sinclair Foundation Research Fellow and joined the faculty in 2000.
Over the past two decades, Dr. Menon’s research has led to major breakthroughs in our understanding of the architecture, function, and development of these large-scale distributed human brain networks. Dr. Menon and his team were among the first to discover that the human brain is organized into specialized and interacting networks of brain regions, which has resulted in a paradigm shift in how we investigate human brain function and cognition. Virtually every psychiatric and neurological disorder has been probed with the scientific framework Dr. Menon and his team first developed. This includes discovery of the default mode, frontoparietal, and salience networks, and their functions, which have led to elucidation of how deficits in access, engagement and disengagement of large-scale brain networks play a prominent role in psychopathology, providing novel insights into brain mechanisms underlying cognitive, affective, and social function and dysfunction that cut across multiple neurological and psychiatric disorders.
Dr. Menon’s research has been cited over 101,000 times, with an h-index of 130 (Google Scholar). Dr. Menon is a ISI Highly Cited Researcher in Neuroscience (2013, 2014, 2015, 2016, 2017, 2018; ISI, Thompson Reuters), and in 2019 and 2020 he was named an ISI Highly Cited Researcher with Cross-Field impact.
Rachael L. and Walter F. Nichols, MD, Professor and Professor, by courtesy, of Education and of Neurology and Neurological Sciences
Bio
Dr. Menon is the Rachel L. and Walter F. Nichols, MD, Professor of Psychiatry & Behavioral Sciences and, Professor, by courtesy, of Neurology & Neurological Sciences and Education at Stanford University. Dr. Menon is director of the Stanford Cognitive and Systems Neuroscience Laboratory, which seeks to advance fundamental knowledge of human brain function and dysfunction, and to use this knowledge to help children and adults with psychiatric and neurological disorders. Research in Dr. Menon's lab emphasizes a tight integration of cognitive, behavioral, neuroscience and computational methodologies. Students and researchers in his lab come from a wide range of disciplines, including psychiatry, neurology, psychology, neuroscience, electrical and biomedical engineering, and computer science, to conduct research in a highly interdisciplinary setting.
Dr. Menon received his BSc (Honors) in physics from the Indian Institute of Technology and his PhD in computer science from the University of Texas at Austin. He did a postdoctoral fellowship in neurophysiology at the University of California, Berkeley under the direction of Prof. Walter J. Freeman, III. He came to Stanford University as a Sinclair Foundation Research Fellow and joined the faculty in 2000.
Over the past two decades, Dr. Menon’s research has led to major breakthroughs in our understanding of the architecture, function, and development of these large-scale distributed human brain networks. Dr. Menon and his team were among the first to discover that the human brain is organized into specialized and interacting networks of brain regions, which has resulted in a paradigm shift in how we investigate human brain function and cognition. Virtually every psychiatric and neurological disorder has been probed with the scientific framework Dr. Menon and his team first developed. This includes discovery of the default mode, frontoparietal, and salience networks, and their functions, which have led to elucidation of how deficits in access, engagement and disengagement of large-scale brain networks play a prominent role in psychopathology, providing novel insights into brain mechanisms underlying cognitive, affective, and social function and dysfunction that cut across multiple neurological and psychiatric disorders.
Dr. Menon’s research has been cited over 101,000 times, with an h-index of 130 (Google Scholar). Dr. Menon is a ISI Highly Cited Researcher in Neuroscience (2013, 2014, 2015, 2016, 2017, 2018; ISI, Thompson Reuters), and in 2019 and 2020 he was named an ISI Highly Cited Researcher with Cross-Field impact.
This profile is not available
Moderator
This profile is not available
Associate Professor of Neurology and Neurological Sciences (Neurology Research Faculty)
This profile is not available
Speaker
Robert W. and Vivian K. Cahill Professor of Cancer Research
Moderator
Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Bio
Latha Palaniappan MD, MS, is Associate Dean for Research, and clinical and population researcher. Her research has focused on the study of diverse populations, chronic disease and prevention. Dr. Palaniappan specifically seeks to address the gap in knowledge of health in Asian subgroups and other understudied racial/ethnic minorities (PACS 5R01DK081371, CASPER R01HL126172, and CAUSES R01MD007012). Her current work examines the clinical effectiveness of structured physical activity programs for diabetes management (Initiate and Maintain Physical Activity in Clinics - IMPACT, 5R18DK096394), as well as best exercise regimens for normal-weight diabetics (Strength Training Regimen for Normal Weight Diabetics - STRONG-D, 2R01DK081371). She was recently renewed as a Midcareer Investigator Award (K24 HL150476) by the National Institutes of Health to provide mentoring to junior clinical investigators in the conduct of patient oriented research. She is currently working on implementation of evidence based genetic and pharmacogenetic testing in clinical settings. She received a Fulbright Award in 2022 to work with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) on implementation of Precision Health in Australia. Dr. Palaniappan is the Faculty co-Director of the Stanford Biobank (with Drs. Brooke Howitt and Joachim Hallmayer) designed to accelerate translatable scientific discoveries. She co-founded (with Dr. Bryant Lin) the Center for Asian American, Native Hawaiian and Pacific Islander Health Research and Education (CARE) at Stanford in 2018.
Refreshments will be available in the lobby.
Speakers
Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Bio
Latha Palaniappan MD, MS, is Associate Dean for Research, and clinical and population researcher. Her research has focused on the study of diverse populations, chronic disease and prevention. Dr. Palaniappan specifically seeks to address the gap in knowledge of health in Asian subgroups and other understudied racial/ethnic minorities (PACS 5R01DK081371, CASPER R01HL126172, and CAUSES R01MD007012). Her current work examines the clinical effectiveness of structured physical activity programs for diabetes management (Initiate and Maintain Physical Activity in Clinics - IMPACT, 5R18DK096394), as well as best exercise regimens for normal-weight diabetics (Strength Training Regimen for Normal Weight Diabetics - STRONG-D, 2R01DK081371). She was recently renewed as a Midcareer Investigator Award (K24 HL150476) by the National Institutes of Health to provide mentoring to junior clinical investigators in the conduct of patient oriented research. She is currently working on implementation of evidence based genetic and pharmacogenetic testing in clinical settings. She received a Fulbright Award in 2022 to work with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) on implementation of Precision Health in Australia. Dr. Palaniappan is the Faculty co-Director of the Stanford Biobank (with Drs. Brooke Howitt and Joachim Hallmayer) designed to accelerate translatable scientific discoveries. She co-founded (with Dr. Bryant Lin) the Center for Asian American, Native Hawaiian and Pacific Islander Health Research and Education (CARE) at Stanford in 2018.
Professor of Medicine (Stanford Prevention Research Center), of Epidemiology and Population Health and, by courtesy, of Biomedical Data Science
Bio
My work aims to improve research methods and practices and to enhance approaches to integrating information and generating reliable evidence. Science is the best thing that can happen to humans, but doing research is like swimming in an ocean at night. Science thrives in darkness. Born in New York City (1965), raised in Athens. Valedictorian (1984), Athens College; National Award, Greek Mathematical Society (1984); MD (top rank of medical school class) from National University of Athens (1990); also received DSc in biopathology from same institution. Trained at Harvard and Tufts (internal medicine, Infectious diseases), then held positions at NIH, Johns Hopkins, Tufts. Chaired the Department of Hygiene and Epidemiology, University of Ioannina Medical School (1999-2010) while also holding adjunct professor positions at Harvard, Tufts, and Imperial College. Moved to Stanford in 2010, initially as Director/C.F. Rehnborg Chair at Stanford Prevention Research Center, then diversified with appointments in 4 departments and membership in 8 centers/institutes at Stanford. Launched the PhD program in Epidemiology & Clinical Research and the MS program in Community Health & Prevention Research. Launched METRICS in 2014. NCI/NIH Senior Advisor on Knowledge Integration (2012-6). President (2023-4), Association of American Physicians. President, Society for Research Synthesis Methodology. Editorial board member of many leading journals (including PLoS Medicine, Lancet, Annals of Internal Medicine, JNCI) and Editor-in-Chief of European Journal of Clinical Investigation (2010-2019). Delivered ~700 invited and honorary lectures. Recipient of many awards (e.g. European Award for Excellence in Clinical Science [2007], Medal for Distinguished Service, Teachers College, Columbia U [2015], Chanchlani Global Health Award [2017], Epiphany Science Courage Award [2018], Einstein fellow [2018], Gordon award [2019], Albert Stuyvenberg Medal (2021), Harwood Prize [2022], Founders' Medal for Lifetime Contributions to Meta-science [2024], Outstanding Reproducibility in Science award [2025]). Inducted in Association of American Physicians (2009), European Academy of Cancer Sciences (2010) American Epidemiological Society (2015), European Academy of Sciences and Arts (2015), National Academy of Medicine (2018), Accademia delle Scienze (Bologna) (2021). Honorary titles from FORTH (2014) and Ioannina (2015), honorary doctorates from Rotterdam (2015), Athens (2017), Tilburg (2019), Edinburgh (2021), Thessaloniki (2023), McMaster (/2024), Woxsen (2025). Multiple honorary lectureships/visiting professorships (Caltech/Oxford/LSHTM/Yale/U Utah/U Conn/UC Davis/U Penn/Wash U St. Louis/NIH/Cedars-Sinai among others). The PLoS Medicine paper on “Why most published research findings are false” is the most-accessed article in the history of Public Library of Science (>3 million hits). Author of 10 literary books, three shortlisted for best book of the year Anagnostis awards in Greece. Brave Thinker scientist for 2010 per Atlantic, “may be one of the most influential scientists alive”. Highly Cited Researcher (Clarivate) in Clinical Medicine, Social Sciences and Psychiatry/Psychology. h=275 (Google Scholar), current citation rate: 6,000 new citations per month (among the 6 scientists worldwide who are currently the most commonly cited). When contrasted against my vast ignorance, these values offer excellent proof that citation metrics can be horribly unreliable. I have no personal social media accounts - I admire people who can outpour their error-free wisdom in them, but I make many errors, I need to revisit my writings multiple times before publishing, and see no reason to make a fool of myself more frequently than sadly unavoidable. I consider myself privileged to have learned and to continue to learn from interactions with students and young scientists (of all ages) from all over the world and I love to be constantly reminded that I know next to nothing.
Professor of Medicine (Stanford Prevention Research Center), of Epidemiology and Population Health and, by courtesy, of Biomedical Data Science
Bio
My work aims to improve research methods and practices and to enhance approaches to integrating information and generating reliable evidence. Science is the best thing that can happen to humans, but doing research is like swimming in an ocean at night. Science thrives in darkness. Born in New York City (1965), raised in Athens. Valedictorian (1984), Athens College; National Award, Greek Mathematical Society (1984); MD (top rank of medical school class) from National University of Athens (1990); also received DSc in biopathology from same institution. Trained at Harvard and Tufts (internal medicine, Infectious diseases), then held positions at NIH, Johns Hopkins, Tufts. Chaired the Department of Hygiene and Epidemiology, University of Ioannina Medical School (1999-2010) while also holding adjunct professor positions at Harvard, Tufts, and Imperial College. Moved to Stanford in 2010, initially as Director/C.F. Rehnborg Chair at Stanford Prevention Research Center, then diversified with appointments in 4 departments and membership in 8 centers/institutes at Stanford. Launched the PhD program in Epidemiology & Clinical Research and the MS program in Community Health & Prevention Research. Launched METRICS in 2014. NCI/NIH Senior Advisor on Knowledge Integration (2012-6). President (2023-4), Association of American Physicians. President, Society for Research Synthesis Methodology. Editorial board member of many leading journals (including PLoS Medicine, Lancet, Annals of Internal Medicine, JNCI) and Editor-in-Chief of European Journal of Clinical Investigation (2010-2019). Delivered ~700 invited and honorary lectures. Recipient of many awards (e.g. European Award for Excellence in Clinical Science [2007], Medal for Distinguished Service, Teachers College, Columbia U [2015], Chanchlani Global Health Award [2017], Epiphany Science Courage Award [2018], Einstein fellow [2018], Gordon award [2019], Albert Stuyvenberg Medal (2021), Harwood Prize [2022], Founders' Medal for Lifetime Contributions to Meta-science [2024], Outstanding Reproducibility in Science award [2025]). Inducted in Association of American Physicians (2009), European Academy of Cancer Sciences (2010) American Epidemiological Society (2015), European Academy of Sciences and Arts (2015), National Academy of Medicine (2018), Accademia delle Scienze (Bologna) (2021). Honorary titles from FORTH (2014) and Ioannina (2015), honorary doctorates from Rotterdam (2015), Athens (2017), Tilburg (2019), Edinburgh (2021), Thessaloniki (2023), McMaster (/2024), Woxsen (2025). Multiple honorary lectureships/visiting professorships (Caltech/Oxford/LSHTM/Yale/U Utah/U Conn/UC Davis/U Penn/Wash U St. Louis/NIH/Cedars-Sinai among others). The PLoS Medicine paper on “Why most published research findings are false” is the most-accessed article in the history of Public Library of Science (>3 million hits). Author of 10 literary books, three shortlisted for best book of the year Anagnostis awards in Greece. Brave Thinker scientist for 2010 per Atlantic, “may be one of the most influential scientists alive”. Highly Cited Researcher (Clarivate) in Clinical Medicine, Social Sciences and Psychiatry/Psychology. h=275 (Google Scholar), current citation rate: 6,000 new citations per month (among the 6 scientists worldwide who are currently the most commonly cited). When contrasted against my vast ignorance, these values offer excellent proof that citation metrics can be horribly unreliable. I have no personal social media accounts - I admire people who can outpour their error-free wisdom in them, but I make many errors, I need to revisit my writings multiple times before publishing, and see no reason to make a fool of myself more frequently than sadly unavoidable. I consider myself privileged to have learned and to continue to learn from interactions with students and young scientists (of all ages) from all over the world and I love to be constantly reminded that I know next to nothing.
Professor of Medicine (Stanford Prevention Research Center), of Epidemiology and Population Health and, by courtesy, of Biomedical Data Science
Bio
My work aims to improve research methods and practices and to enhance approaches to integrating information and generating reliable evidence. Science is the best thing that can happen to humans, but doing research is like swimming in an ocean at night. Science thrives in darkness. Born in New York City (1965), raised in Athens. Valedictorian (1984), Athens College; National Award, Greek Mathematical Society (1984); MD (top rank of medical school class) from National University of Athens (1990); also received DSc in biopathology from same institution. Trained at Harvard and Tufts (internal medicine, Infectious diseases), then held positions at NIH, Johns Hopkins, Tufts. Chaired the Department of Hygiene and Epidemiology, University of Ioannina Medical School (1999-2010) while also holding adjunct professor positions at Harvard, Tufts, and Imperial College. Moved to Stanford in 2010, initially as Director/C.F. Rehnborg Chair at Stanford Prevention Research Center, then diversified with appointments in 4 departments and membership in 8 centers/institutes at Stanford. Launched the PhD program in Epidemiology & Clinical Research and the MS program in Community Health & Prevention Research. Launched METRICS in 2014. NCI/NIH Senior Advisor on Knowledge Integration (2012-6). President (2023-4), Association of American Physicians. President, Society for Research Synthesis Methodology. Editorial board member of many leading journals (including PLoS Medicine, Lancet, Annals of Internal Medicine, JNCI) and Editor-in-Chief of European Journal of Clinical Investigation (2010-2019). Delivered ~700 invited and honorary lectures. Recipient of many awards (e.g. European Award for Excellence in Clinical Science [2007], Medal for Distinguished Service, Teachers College, Columbia U [2015], Chanchlani Global Health Award [2017], Epiphany Science Courage Award [2018], Einstein fellow [2018], Gordon award [2019], Albert Stuyvenberg Medal (2021), Harwood Prize [2022], Founders' Medal for Lifetime Contributions to Meta-science [2024], Outstanding Reproducibility in Science award [2025]). Inducted in Association of American Physicians (2009), European Academy of Cancer Sciences (2010) American Epidemiological Society (2015), European Academy of Sciences and Arts (2015), National Academy of Medicine (2018), Accademia delle Scienze (Bologna) (2021). Honorary titles from FORTH (2014) and Ioannina (2015), honorary doctorates from Rotterdam (2015), Athens (2017), Tilburg (2019), Edinburgh (2021), Thessaloniki (2023), McMaster (/2024), Woxsen (2025). Multiple honorary lectureships/visiting professorships (Caltech/Oxford/LSHTM/Yale/U Utah/U Conn/UC Davis/U Penn/Wash U St. Louis/NIH/Cedars-Sinai among others). The PLoS Medicine paper on “Why most published research findings are false” is the most-accessed article in the history of Public Library of Science (>3 million hits). Author of 10 literary books, three shortlisted for best book of the year Anagnostis awards in Greece. Brave Thinker scientist for 2010 per Atlantic, “may be one of the most influential scientists alive”. Highly Cited Researcher (Clarivate) in Clinical Medicine, Social Sciences and Psychiatry/Psychology. h=275 (Google Scholar), current citation rate: 6,000 new citations per month (among the 6 scientists worldwide who are currently the most commonly cited). When contrasted against my vast ignorance, these values offer excellent proof that citation metrics can be horribly unreliable. I have no personal social media accounts - I admire people who can outpour their error-free wisdom in them, but I make many errors, I need to revisit my writings multiple times before publishing, and see no reason to make a fool of myself more frequently than sadly unavoidable. I consider myself privileged to have learned and to continue to learn from interactions with students and young scientists (of all ages) from all over the world and I love to be constantly reminded that I know next to nothing.
This profile is not available
Moderators
Kenneth Fong Professor and Professor of Bioengineering, of Genetics, of Medicine, of Biomedical Data Science, Senior Fellow at the Stanford Institute for Human-Centered AI and Professor, by courtesy, of Computer Science
Bio
Russ Biagio Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science) and past chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing (AI, data science and informatics) to problems relevant to medicine. He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels. His lab studies how human genetic variation impacts drug response (e.g., http://www.pharmgkb.org/). Other work focuses on the analysis of biological molecules to understand the actions, interactions and adverse events of drugs (e.g., http://helix.stanford.edu/). He helps lead an FDA-supported Center of Excellence in Regulatory Science & Innovation.
Dr. Altman holds an AB from Harvard College, and an MD from Stanford Medical School, and a PhD in Medical Information Sciences from Stanford. He received the U.S. Presidential Early Career Award for Scientists and Engineers and a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians (ACP), the American College of Medical Informatics (ACMI), the American Institute of Medical and Biological Engineering (AIMBE), and the American Association for the Advancement of Science (AAAS). He is a member of the National Academy of Medicine. He is a past-president, founding board member, and a fellow of the International Society for Computational Biology (ISCB), and a past-president of the American Society for Clinical Pharmacology & Therapeutics (ASCPT). He has chaired the Science Board advising the FDA commissioner, and has served on the NIH Director’s Advisory Committee, and as cochair of the IOM Drug Forum. He is an organizer of the annual Pacific Symposium on Biocomputing, and a founder of Personalis (NASDAQ: PSNL). Dr. Altman is board certified in Internal Medicine and in Clinical Informatics. He received the Stanford Medical School graduate teaching award in 2000 and 2020, and the mentorship award in 2014. He is the founding editor of the Annual Reviews of Biomedical Data Science, and hosts a podcast entitled “The Future of Everything.”
Kenneth Fong Professor and Professor of Bioengineering, of Genetics, of Medicine, of Biomedical Data Science, Senior Fellow at the Stanford Institute for Human-Centered AI and Professor, by courtesy, of Computer Science
Bio
Russ Biagio Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science) and past chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing (AI, data science and informatics) to problems relevant to medicine. He is particularly interested in methods for understanding drug action at molecular, cellular, organism and population levels. His lab studies how human genetic variation impacts drug response (e.g., http://www.pharmgkb.org/). Other work focuses on the analysis of biological molecules to understand the actions, interactions and adverse events of drugs (e.g., http://helix.stanford.edu/). He helps lead an FDA-supported Center of Excellence in Regulatory Science & Innovation.
Dr. Altman holds an AB from Harvard College, and an MD from Stanford Medical School, and a PhD in Medical Information Sciences from Stanford. He received the U.S. Presidential Early Career Award for Scientists and Engineers and a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians (ACP), the American College of Medical Informatics (ACMI), the American Institute of Medical and Biological Engineering (AIMBE), and the American Association for the Advancement of Science (AAAS). He is a member of the National Academy of Medicine. He is a past-president, founding board member, and a fellow of the International Society for Computational Biology (ISCB), and a past-president of the American Society for Clinical Pharmacology & Therapeutics (ASCPT). He has chaired the Science Board advising the FDA commissioner, and has served on the NIH Director’s Advisory Committee, and as cochair of the IOM Drug Forum. He is an organizer of the annual Pacific Symposium on Biocomputing, and a founder of Personalis (NASDAQ: PSNL). Dr. Altman is board certified in Internal Medicine and in Clinical Informatics. He received the Stanford Medical School graduate teaching award in 2000 and 2020, and the mentorship award in 2014. He is the founding editor of the Annual Reviews of Biomedical Data Science, and hosts a podcast entitled “The Future of Everything.”
This profile is not available
Closing remarks by members of the symposium committees.
More information to follow.